Zydus Cadila begins human trials of COVID-19 vaccine candidate ZyCoV-D in 1,000 volunteers
Zydus is only the second Indian pharma firm to get DCGI's nod for human trials of its vaccine candidate.
Drug firm Zydus Cadila on Wednesday said it has started human clinical trials of its COVID-19 vaccine candidate ZyCoV-D.
In the phase of trials, the company will be enrolling over 1,000 subjects across multiple clinical study sites in India, it said in a regulatory filing.
The adaptive phase I/ II human clinical trials of ZyCoV-D have commenced with the first human dosing, it said, adding that the adaptive phase I/II dose escalation, multi-centric study will assess the safety, tolerability and immunogenicity of the vaccine.
Earlier this month, Zydus had received approval from domestic authorities to start human trials for its COVID-19 vaccine contender – the second Indian pharmaceutical firm to get such nod amid a surge in novel coronavirus infections worldwide.
It got approval a few days after India's first indigenous COVID-19 vaccine candidate COVAXIN, developed by city-based Bharat Biotech in collaboration with Indian Council of Medical Research and National Institute of Virology, got the nod for human clinical trials from the Drug Controller General of India.
Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 356.50 apiece on BSE, up 0.81 per cent against their previous close.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
AstraZeneca's COVID-19 vaccine trial paused after 'potentially unexplained' adverse reaction in participant
In a statement issued on Tuesday evening, AstraZeneca said its "standard review process triggered a pause to vaccination to allow review of safety data"
He also said, “The anti-vaccine movement, they can build narratives to fight against vaccines but the track record of vaccines tells its own story and people should not be confused."
Bharat Bio's COVAXIN: Ten takeaways from successful animal trials of the experimental COVID-19 vaccine
The animal trials demonstrate that COVAXIN protected against SARS-CoV-2, and amped up two kinds of antibodies needed for a strong immune response against the virus.